Home/Pipeline/nAV-101

nAV-101

Amyotrophic Lateral Sclerosis (ALS)

Pre-clinicalActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Pre-clinical

Status

Active

Company

nVector

About nVector

nVector is a private, pre-clinical stage biotech firm founded in 2016, operating at the intersection of drug delivery and viral technology. The company's primary asset is its proprietary GreenGlia™ AAV platform, featuring a library of over 10 million capsid variants engineered for superior targeting and distribution within the brain and spinal cord. In addition to its internal therapeutic pipeline targeting neurodegenerative diseases, nVector offers platform licensing and custom capsid engineering services to partners, alongside a biomarker testing and development service led by industry veterans. The company appears to be pre-revenue, focusing on platform validation and partnership development to advance its technologies and programs.

View full company profile

Therapeutic Areas

Amyotrophic Lateral Sclerosis (ALS)Parkinson's Disease Huntington's Disease Alzheimer's Disease Traumatic Brain Injury

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active
NG CELL	NeuroGenesis Bio	Phase 2	Active